… of multiple sclerosis, people with this disease are likely to benefit from rehabilitation therapy
throughout … The review provides an update on rehabilitation focused on balance and walking …

… The short-term clinical inputs for the model for Sativex-treated … , placebo-controlled clinical
trial with Sativex in MS spasticity (n … The titration schedule specified in the Sativex Summary of …

… It was not the intention of this review to provide a summary … which placebo data to use
when comparing more than one … of relapses, and their often short-term nature, together with a …

… Summary: MS relapses need to be recognized in a timely … ), and oral placebo (n = 150) for
14 days in the treatment of 457 … corticosteroid therapy; however, short-term steroid treatment …

… first 2 years in the placebo group, treatment may avoid one … Table 1 contains summary cost
data, stratified by gender and … chronic diseases, using available short-term evidence. It is not …

… Jurg Kesselring, in a recent excellent review of the subject, ended by stating ‘an
important continuing task is to increase acceptance of rehabilitation as a valuable treatment …

… PLOS Medicine publishes research and commentary of … , expensive interventions (or those
believed to be expensive … any physical or informational materials used in the placebo/sham …

… in the placebo trial arm, the standard DMD treatment arm and the … In the short term, a realistic
aim may be the inclusion of a … For their comments on earlier drafts of this review, the authors …

… gained from rehabilitation are neither short term, nor disproportionately expensive, when …
In summary, we recognise that there is an urgent need for well-conducted longer-term trials …

… This information is valuable both for assessing the validity of … or short-term conditions,
double-blinded trials with a placebo … In summary, SPIN is a unique endeavour to develop and test …